Scholarlink

Purpose <p>To evaluate the intraocular pressure (IOP)-lowering efficacy and treatment stability of ripasudil-brimonidine fixed-dose combination (RBFC) in patients with secondary glaucoma associated with uveitis.</p> Study design <p>Single-center, retrospective study.</p> Methods <p>Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH; <i>n</i> = 19), steroid-induced OH (<i>n</i> = 18), and primary open-angle glaucoma (POAG; <i>n</i> = 13). Clinical parameters—including IOP, visual acuity (VA), and medication score—were assessed at baseline, the first follow-up, and the final visit.</p> Results <p>In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (<i>P</i>&#xa0;&lt; 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group.</p> Conclusion <p>RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Kenji Miyao,
  • Masaya Imazeki,
  • Tomoyuki Oyama,
  • Shunsaku Nakai,
  • Takayuki Kanda,
  • Masaru Takeuchi

摘要

Purpose

To evaluate the intraocular pressure (IOP)-lowering efficacy and treatment stability of ripasudil-brimonidine fixed-dose combination (RBFC) in patients with secondary glaucoma associated with uveitis.

Study design

Single-center, retrospective study.

Methods

Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH; n = 19), steroid-induced OH (n = 18), and primary open-angle glaucoma (POAG; n = 13). Clinical parameters—including IOP, visual acuity (VA), and medication score—were assessed at baseline, the first follow-up, and the final visit.

Results

In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (P < 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group.

Conclusion

RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.